Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2023 | Implications of extended dosing of natalizumab on wearing-off symptoms in MS patients

Alyssa Toorop, MD, PhD, Amsterdam University Medical Centers, Amsterdam, The Netherlands, sheds light on the wearing-off symptoms often seen in multiple sclerosis (MS) patients undergoing natalizumab treatment, particularly emphasizing symptoms such as fatigue. With extended interval dosing gaining popularity, understanding its effects on these symptoms is crucial. While some anticipated that extended dosing could amplify the wearing-off symptoms, the NEXT-MS study indicated that the symptoms remained consistent regardless of dosing intervals. However, biases due to the non-randomized nature of the study were acknowledged. Dr Toorop also highlights conflicting results from other research and emphasizes the importance of open patient-neurologist communication when considering treatment adjustments. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


The NEXT-MS trial was funded by the Dutch MS Research Foundation, the Brain Foundation Netherlands, and Innovation Funds Healthcare insurers. The funding sources had no involvement in the execution of the study.